|Bid||479.60 x 0|
|Ask||480.20 x 0|
|Day's range||476.90 - 483.40|
|52-week range||389.55 - 585.50|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||23.50|
|Earnings date||06-Aug-2019 - 10-Aug-2019|
|Forward dividend & yield||3.00 (0.63%)|
|1y target est||N/A|
Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Ambrisentan tablets, indicated for the treatment of pulmonary arterial hypertension.
Cipla Ltd, India's second-largest generic drugmaker by market capitalisation, reported on Wednesday a 17.1 percent drop in quarterly profit, dragged down by higher tax expenses and weak sales in domestic ...